Market Cap 50.46M
Revenue (ttm) 128.94M
Net Income (ttm) -85.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -66.23%
Debt to Equity Ratio 0.00
Volume 25,379
Avg Vol 57,608
Day's Range N/A - N/A
Shares Out 5.96M
Stochastic %K 86%
Beta 0.18
Analysts Sell
Price Target $14.00

Company Profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Ket...

Industry: Biotechnology
Sector: Healthcare
Phone: 805 623 4211
Address:
1280 Rancho Conejo Blvd, Thousand Oaks, United States
Smurfologist
Smurfologist Jul. 3 at 4:22 PM
I love the way $ATRA has been slowly going up. And, even when it drops, it recovers nicely.......Gotta love this stock🙏🏾🐃💪🏾💣💥🚀
0 · Reply
VENIVICI
VENIVICI Jun. 30 at 11:44 PM
$ATRA Time to offload the boat. Been dragging this bullet since the CRL... With no sign of that gap getting filled anytime soon it's probably time to let it go !!!!!!
2 · Reply
takingstock73
takingstock73 Jun. 23 at 9:24 PM
$ATRA anyone have a beat on when we can expect some news here ?
1 · Reply
TrkDvr
TrkDvr Jun. 20 at 3:19 PM
$ATRA Looks like they'll need to do another funding round. Probably have been waiting for the FDA approval.
6 · Reply
ballyhooo
ballyhooo Jun. 18 at 2:44 PM
$ATRA Pierre Fabre Laboratories Begins Next Chapter in Secaucus, NJ
1 · Reply
VENIVICI
VENIVICI Jun. 17 at 5:59 PM
$ATRA Does anyone know when the Type A meeting between ATRA and the FDA is scheduled? And any thoughts on how long it might take from the meeting to resubmission....
0 · Reply
BullRun4
BullRun4 Jun. 16 at 11:19 PM
$ATRA by when do they expect the FDA to give them a thumbs up and a go forward with approval? Q1 2026?
2 · Reply
takingstock73
takingstock73 Jun. 11 at 7:41 PM
$ATRA low vol sell off , this is a buying opportunity
0 · Reply
Smurfologist
Smurfologist Jun. 10 at 12:53 PM
$ATRA Is $9.75 too much to ask for?!? TYME TO GAP UP!!!🙏🏾🐃💪🏾💣💥🚀
0 · Reply
Danny_vdw74
Danny_vdw74 Jun. 9 at 5:36 PM
$ATRA 📅 Upcoming Events Annual Shareholders Meeting: The Annual Shareholders Meeting will take place on June 10, 2025, at 9:00 AM PDT. This is an important opportunity for shareholders to receive updates on the company's strategy, performance, and future outlook. --- 🧬 Clinical and Strategic Updates EBVALLO™ (tabelecleucel): The FDA has lifted the clinical hold, allowing Atara to resume the Phase 3 ALLELE study for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD). In addition, a Type A meeting is scheduled for Q2 2025 to discuss the approach for the resubmission of the Biologics License Application (BLA) for potential FDA approval.
0 · Reply
Latest News on ATRA
US FDA declines to approve Atara Biotherapeutics' cancer therapy

Jan 16, 2025, 8:41 AM EST - 6 months ago

US FDA declines to approve Atara Biotherapeutics' cancer therapy


Smurfologist
Smurfologist Jul. 3 at 4:22 PM
I love the way $ATRA has been slowly going up. And, even when it drops, it recovers nicely.......Gotta love this stock🙏🏾🐃💪🏾💣💥🚀
0 · Reply
VENIVICI
VENIVICI Jun. 30 at 11:44 PM
$ATRA Time to offload the boat. Been dragging this bullet since the CRL... With no sign of that gap getting filled anytime soon it's probably time to let it go !!!!!!
2 · Reply
takingstock73
takingstock73 Jun. 23 at 9:24 PM
$ATRA anyone have a beat on when we can expect some news here ?
1 · Reply
TrkDvr
TrkDvr Jun. 20 at 3:19 PM
$ATRA Looks like they'll need to do another funding round. Probably have been waiting for the FDA approval.
6 · Reply
ballyhooo
ballyhooo Jun. 18 at 2:44 PM
$ATRA Pierre Fabre Laboratories Begins Next Chapter in Secaucus, NJ
1 · Reply
VENIVICI
VENIVICI Jun. 17 at 5:59 PM
$ATRA Does anyone know when the Type A meeting between ATRA and the FDA is scheduled? And any thoughts on how long it might take from the meeting to resubmission....
0 · Reply
BullRun4
BullRun4 Jun. 16 at 11:19 PM
$ATRA by when do they expect the FDA to give them a thumbs up and a go forward with approval? Q1 2026?
2 · Reply
takingstock73
takingstock73 Jun. 11 at 7:41 PM
$ATRA low vol sell off , this is a buying opportunity
0 · Reply
Smurfologist
Smurfologist Jun. 10 at 12:53 PM
$ATRA Is $9.75 too much to ask for?!? TYME TO GAP UP!!!🙏🏾🐃💪🏾💣💥🚀
0 · Reply
Danny_vdw74
Danny_vdw74 Jun. 9 at 5:36 PM
$ATRA 📅 Upcoming Events Annual Shareholders Meeting: The Annual Shareholders Meeting will take place on June 10, 2025, at 9:00 AM PDT. This is an important opportunity for shareholders to receive updates on the company's strategy, performance, and future outlook. --- 🧬 Clinical and Strategic Updates EBVALLO™ (tabelecleucel): The FDA has lifted the clinical hold, allowing Atara to resume the Phase 3 ALLELE study for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD). In addition, a Type A meeting is scheduled for Q2 2025 to discuss the approach for the resubmission of the Biologics License Application (BLA) for potential FDA approval.
0 · Reply
Smurfologist
Smurfologist Jun. 9 at 1:51 PM
$ATRA Is $9.75 too much to ask for on a Monday?!? LET'S GO!!!!🙏🏾🐃💪🏾💣💥🚀
0 · Reply
Vakeshka
Vakeshka Jun. 8 at 4:40 PM
$ATRA institutions loading up. On May 16, 2025, Redmile Group, LLC executed a notable transaction involving Atara Biotherapeutics Inc. The firm added 263,506 shares of Atara Biotherapeutics Inc at a trade price of $6.84 per share. This strategic move highlights Redmile Group's continued interest in the biotechnology sector, particularly in companies with potential for transformative therapies. The transaction reflects a calculated decision to increase their stake in Atara Biotherapeutics, a company focused on developing treatments for serious diseases. The recent transaction increased Redmile Group's total holdings in Atara Biotherapeutics to 705,207 shares. This addition represents a 0.46% position in the firm's portfolio and a 9.90% stake in Atara Biotherapeutics. The transaction underscores Redmile Group's confidence in Atara Biotherapeutics' potential...By increasing its stake, Redmile Group aims to capitalize on the potential upside of Atara Biotherapeutics' innovative therapies
0 · Reply
ezimon
ezimon Jun. 6 at 10:12 PM
$ATRA yes, in theory it should had been around $16 - $18 for the last 4 months, so it may be that it is catching up :-)
0 · Reply
Smurfologist
Smurfologist Jun. 6 at 6:24 PM
$ATRA $9.25 is on the horizon after hitting $9.20......LET'S GO!!!!!🙏🏾🐃💪🏾💣💥🚀
0 · Reply
hassle
hassle Jun. 6 at 6:03 PM
$ATRA there are no news whatsoever in the last 20 days, why this is constantly going up? anything i might be missing?
0 · Reply
Smurfologist
Smurfologist Jun. 6 at 4:57 PM
$ATRA JUST PLAIN WoW!!! Next stop: $9.15?!?🙏🏾🐃💪🏾💣💥🚀
0 · Reply
Smurfologist
Smurfologist Jun. 6 at 3:08 PM
$ATRA is on the cusp of being a monster stock; yawl betta recognize!!! So Purdy!!!🙏🏾🐃💪🏾💣💥🚀
0 · Reply
Smurfologist
Smurfologist Jun. 6 at 3:02 PM
$ATRA JUST WoW!!!!!🙏🏾🐃💪🏾💣💥🚀
0 · Reply
Smurfologist
Smurfologist Jun. 6 at 2:31 PM
$ATRA Is $9.00 too much to ask for?!? LET'S GO!!!!🙏🏾🐃💪🏾💣💥🚀
0 · Reply
Smurfologist
Smurfologist Jun. 6 at 1:46 PM
$ATRA Nice rise all week 🙏🏾🐃💪🏾💣💥🚀
0 · Reply
Smurfologist
Smurfologist Jun. 5 at 5:05 PM
$ATRA Just WoW!!!🙏🏾💪🏾💣💥🚀
0 · Reply
Smurfologist
Smurfologist Jun. 4 at 5:04 PM
$ATRA WoW!!!💪🏾💣💥🚀
0 · Reply